Immunic (IMUX) Liabilities and Shareholders Equity (2013 - 2026)

Immunic has disclosed Liabilities and Shareholders Equity across 14 years of filings, most recently posting $189.7 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $189.7 million, up 824.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $315.9 million (up 48.58% YoY), and the FY2025 annual result was $24.1 million, down 41.15% from the prior year.
• Liabilities and Shareholders Equity came in at $189.7 million for Q1 2026 at Immunic, up from $24.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $189.7 million in Q1 2026 to a low of $20.5 million in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $86.5 million (2024), against an average of $87.6 million.
• Across the five-year window, Liabilities and Shareholders Equity slumped 80.3% in 2025 and jumped 824.89% in 2026, its largest moves.
• Immunic's Liabilities and Shareholders Equity stood at $127.8 million in 2022, then plunged by 57.5% to $54.3 million in 2023, then slipped by 24.74% to $40.9 million in 2024, then tumbled by 41.15% to $24.1 million in 2025, then jumped by 688.88% to $189.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $189.7 million (Q1 2026), $24.1 million (Q4 2025), and $40.7 million (Q3 2025), per Business Quant data.